

IN THE CLAIMS

Please cancel claims 1-6, and 11-19.

Please amend claims 7, 8, and 20 as follows:

1 7. (Amended) A binding compound comprising an antigen binding site from an
2 antibody, which specifically binds to a mature polypeptide comprising at least 8 contiguous
3 amino acid residues from[:

- 4 a)] SEQ ID NO: 2[;
5 b) SEQ ID NO: 6;
6 c) SEQ ID NO: 13; or
7 d) SEQ ID NO: 15].

1 8. (Amended) The binding compound of Claim 7, wherein[:

- 2 a)] said binding compound is an Fv, Fab, or Fab2 fragment[;
3 b) said binding compound is conjugated to another chemical moiety; or
4 c) said antibody:
5 i) is raised against a polypeptide comprising a 12 consecutive amino acid
6 segment of SEQ ID NO: 2, 6, 13, or 15;
7 ii) is raised against a mature IL-1 ϵ ;
8 iii) is raised to a purified rodent IL-1 δ or rodent or primate IL-1 ϵ ;
9 iv) is immunoselected;
10 v) is a polyclonal antibody;
11 vi) binds to a denatured IL-1 δ or IL-1 ϵ ;
12 vii) exhibits a K_d to antigen of at least 30 μ M;
13 viii) is attached to a solid substrate, including a bead or plastic membrane;
14 ix) is in a sterile composition; or
15 x) is detectably labeled, including a radioactive or fluorescent label].
16

1 20. (Amended) A method of:

- 2 A) making an antiserum comprising an antibody of Claim 7, comprising immunizing a
3 mammal with an immunogenic amount of [:
4 a) a rodent IL-1 δ polypeptide;
5 b)] a peptide [sequence] comprising a 12 consecutive amino acid segment
6 of SEQ ID NO: 2;
7 (c) a rodent or primate IL-1 ϵ polypeptide; or
8

9 d) a peptide sequence comprising a 12 consecutive amino acid segment of
10 SEQ ID NO: 6, 13, or 15;]
11 thereby causing said antiserum to be produced; or

12
13 B) producing an antigen:antibody complex, comprising contacting [:

14 a)] a rodent IL-1 δ protein or peptide with [an antibody] a binding
15 compound of Claim 7; [or

16 b) a rodent or primate IL-1 ϵ protein or peptide with an antibody of Claim
17 7;]

18 thereby allowing said complex to form.

19
1 Please add new claims 21-25 as follows:

1 21. (New) The binding compound of Claim 7, wherein said antibody is a
2 polyclonal antibody.

1 22. (New) The binding compound of Claim 7, wherein said antibody is
2 detectably labeled.

1 23. (New) The binding compound of claim 7, wherein said at least 8
2 contiguous amino acid residues of SEQ ID NO:2 is selected from the group consisting of
3 residues 8-24; 27-48; 56-73; 77-106; 108-125; 130-156; and 74-98.

1 24. (New) The binding compound of claim 7, wherein said polypeptide
2 comprises at least 12 contiguous amino acid residues from SEQ ID NO: 2.

1 25. (New) The binding compound of claim 24, wherein said 12 consecutive
2 amino acid segment is selected from:

3 (1) LeuCysPheArgMetLysAspSerAlaLeuLysValLeuTyrLeuHisAsn-Asn;

4 (2) IleSerValValProAsnArgAlaLeuAspAlaSerLeuSerProValIle-LeuGlyValGln;

5 (3) SerProValIleLeuGlyValGlnGlyGlySerGlnCys;

6 (4) ProIleLeuLysLeuGluProValAsnIleMetGluLeu;